Tafluprost: a novel prostaglandin analog for treatment of glaucoma
Authors:
- 18 August 2011
- journal article
- review article
- Published by Springer Nature in Advances in Therapy
- Vol. 28 (9) , 707-715
Abstract
The objective of this review is to evaluate the safety and efficacy of tafluprost, a fluoroprostaglandin receptor analog, for reduction of intraocular pressure in open angle glaucoma and ocular hypertension. A search of published literature was performed on the PubMed database using the search term “tafluprost.” The literature search identified 48 publications, including clinical and preclinical studies, from 2003 to 2011. From these ressults, articles available in the English language and in full text were selected and systematically reviewed by the authors. Recent studies have shown that tafluprost is an effective IOP-lowering medication. Evidence based medicine also reveals that tafluprost is safe and well-tolerated. Preservative-free tafluprost is as potent as the preserved formulation, but with fewer and milder ocular surface side effects. Since its introduction in 2008, initial studies have demonstrated that preserved and preservative-free tafluprost formulations have proven efficacy and safety in the treatment of glaucoma and ocular hypertension. Larger studies with longer follow-up are needed to assess long-term safety, efficacy, and tolerability compared with other prostaglandin analogs used for treating glaucoma.Keywords
This publication has 37 references indexed in Scilit:
- Use of an Adult Rat Retinal Explant Model for Screening of Potential Retinal Ganglion Cell Neuroprotective TherapiesInvestigative Ophthalmology & Visual Science, 2011
- Effects of prostaglandin F2α analogues on endothelin-1-induced impairment of rabbit ocular blood flow: Comparison among tafluprost, travoprost, and latanoprostExperimental Eye Research, 2010
- Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertensionClinical Ophthalmology, 2010
- Switching from a preserved to a preservative‐free prostaglandin preparation in topical glaucoma medicationActa Ophthalmologica, 2010
- Disposition and Metabolism of a Novel Prostanoid Antiglaucoma Medication, Tafluprost, Following Ocular Administration to RatsDrug Metabolism and Disposition, 2009
- Short-Term Effects of Topical Tafluprost on Retinal Blood Flow in CatsJournal of Ocular Pharmacology and Therapeutics, 2008
- Relaxing effect and mechanism of tafluprost on isolated rabbit ciliary arteriesExperimental Eye Research, 2008
- Pharmacokinetics, efficacy and safety profiles of preserved and preservative‐free tafluprost in healthy volunteersActa Ophthalmologica, 2008
- Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chlorideBritish Journal of Ophthalmology, 2008
- The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient miceBritish Journal of Ophthalmology, 2006